Patients with advanced cancer commonly report depressive symptoms. Examinations of gender differences in depressive symptoms in patients with advanced cancer have yielded inconsistent findings.
Aim:
The objective of this study was to investigate whether the severity and correlates of depressive symptoms differ by gender in patients with advanced cancer.
Design:
Participants completed measures assessing sociodemographic and medical characteristics, disease burden, and psychosocial factors. Depressive symptoms were examined using the Patient Health Questionnaire, and other measures included physical functioning, symptom burden, general anxiety, death related distress, and dimensions of demoralization. A cross-sectional analysis examined the univariate and multivariate relationships between gender and depressive symptoms, while controlling for important covariates in multivariate analyses.
Setting/participants:
Patients with advanced cancer (N = 305, 40% males and 60% females) were recruited for a psychotherapy trial from outpatient oncology clinics at a comprehensive cancer center in Canada.
Results:
Severity of depressive symptoms was similar for males (M = 7.09, SD = 4.59) and females (M = 7.66, SD = 5.01), t(303) = 1.01, p = 0.314. Greater general anxiety and number of cancer symptoms were associated with depressive symptoms in both males and females. Feeling like a failure (β = 0.192), less death anxiety (β = –0.188), severity of cancer symptoms (β = 0.166), and older age (β = 0.161) were associated with depressive symptoms only in males, while disheartenment (β = 0.216) and worse physical functioning (β = 0.275), were associated with depressive symptoms only in females.
Conclusions:
Males and females report similar levels of depressive symptoms but the pathways to depression may differ by gender. These differences suggest the potential for gender-based preventive and therapeutic interventions in this population.
RodinGLoCMikulincerM, et al. Pathways to distress: the multiple determinants of depression, hopelessness, and the desire for hastened death in metastatic cancer patients. Soc Sci Med2009; 68(3): 562–569.
2.
TangPLWangHHChouFH.A systematic review and meta-analysis of demoralization and depression in patients with cancer. Psychosomatics2015; 56(6): 634–643.
3.
RodinGWalshAZimmermannC, et al. The contribution of attachment security and social support to depressive symptoms in patients with metastatic cancer. Psychooncology2007; 16(12): 1080–1091.
4.
LoCZimmermannCRydallA, et al. Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer. J Clin Oncol2010; 28(18): 3084–3089.
5.
HotopfMChidgeyJLyKL.Depression in advanced disease: a systematic review. Palliat Med2002; 16: 81–97.
6.
JanberidzeEHjermstadMJHaugenDF, et al. How are patient populations characterized in studies investigating depression in advanced cancer? Results from a systematic literature review. J Pain Symptom Manage2014; 48(8): 678–698.
7.
MitchellAJChanMBhattiH, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care setting: a meta-analysis of 94 interview based studies. Lancet Oncol2011; 12(2): 160–174.
8.
UllrichAGrubeKHlawatschC, et al. Exploring the gender dimension of problems and needs of patients receiving specialist palliative care in a German palliative care unit - the perspectives of patients and healthcare professionals. BMC Palliat Care2019; 18(1): 59.
9.
HeidariSBaborTFde CastroP, et al. Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev2016; 1(2).
10.
DaySMasonRLagoskyS, et al. Rochon. Integrating and evaluating sex and gender in health research. Health Res Policy Syst2016; 14(1): 75.
11.
WeissmanMMKlermanGL.Sex differences and the epidemiology of depression. Arch Gen Psychiatry1977; 34: 98–111.
12.
SalkRHHydeJSAbramsonLY.Gender differences in depression in representative national samples: meta-analyses of diagnoses and symptoms. Psychol Bull2017; 143(8): 783–822.
13.
BrownGWBifulcoAHarrisT.Life events, vulnerability and onset of depression: some refinements. Br J Psychiatry1987; 150: 30–42.
14.
HammenC.Stress and depression. Ann Rev Clin Psychol2005; 1: 293–319.
15.
StrongVWatersRHibberdC, et al. Emotional distress in cancer patients: the Edinburgh cancer centre symptom study. Br J Cancer2007; 96(6): 868–874.
16.
ShanmugasegaramSRussellKLKovacsAH, et al. Gender and sex differences in prevalence of major depression in coronary artery disease patients: a meta-analysis. Maturitas2012; 73(4): 305–311.
17.
WilsonKGChochinovHMSkirkoMG, et al. Depression and anxiety disorders in palliative cancer care. J Pain Symptom Manage2007; 33: 122–129.
18.
MystakidouKTsilikaEParpaE, et al. Assessment of anxiety and depression in advanced cancer patients and their relationship with quality of life. Qual Life Res2005; 14(8): 1825–1833.
19.
MystakidouKTsilikaEParpaE, et al. Psychological distress of patients with advanced cancer: influence and contribution of pain severity and pain interference. Cancer Nurs2006; 29(5): 400–405.
20.
MystakidouKTsilikaEParpaE, et al. Beck Depression Inventory: exploring its psychometric properties in a palliative care population of advanced cancer patients. Eur J Cancer Care2007; 16: 244–250.
21.
KirkovaJWalshDRybickiL, et al. Symptom severity and distress in advanced cancer. Palliat Med2010; 24(3): 330–339.
22.
BradleyNDavisLChowE.Symptom distress in patients attending an outpatient palliative radiotherapy clinic. J Pain Symptom Manage2005; 30: 123–131.
23.
ZimmermannCBurmanDFollwellM, et al. Predictors of symptom severity and response in patients with metastatic cancer. Am J Hosp Palliat Care2010; 27(3): 175–181.
24.
CulletonSDennisKKooK, et al. Gender difference in symptom presentations among patients with bone metastases in gender-specific and gender-neutral primary cancers. World J Oncol2011; 2(3): 102–112.
25.
HopwoodPStephensRJ.Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol2000; 18: 893–903.
26.
RaynerLLeeWPriceA, et al. The clinical epidemiology of depression in palliative care and the predictive value of somatic symptoms: cross-sectional survey with four-week follow-up. Palliat Med2011; 25(3): 229–241.
27.
HayesRDLeeWRaynerL, et al. Gender differences in prevalence of depression among patients receiving palliative care: the role of dependency. Palliat Med2012; 26(5): 696–702.
28.
MillerSLoCGaglieseL, et al. Patterns of depression in cancer patients: an indirect test of gender-specific vulnerabilities to depression. Soc Psychiatry2011; 46(8): 767–774.
29.
RodinGLoCRydallA, et al. Managing Cancer and Living Meaningfully (CALM): a randomized controlled trial of a psychological intervention for patients with advanced cancer. J Clin Oncol2018; 36(23): 2422–2432.
30.
KatzmanRBrownTFuldP, et al. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry1983; 140: 734–739.
31.
KroenkeKSpitzerRLWilliamsJB.The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med2001; 16(9): 606–613.
32.
HinzAMehnertAKocaleventR-D, et al. Assessment of depression severity with the PHQ-9 in cancer patients and in the general population. BMC Psychiatry2016; 16(1): 22.
33.
ElhaiJDContractorAATamburrinoM, et al. The factor structure of major depression symptoms: a test of four competing models using the Patient Health Questionnaire-9. Psychiatry Res2012; 199: 169–173.
34.
ChilcotJRaynerLLeeW, et al. The factor structure of the PHQ-9 in palliative care. J Psychosom Res2013; 75(1): 60–64.
35.
TibubosANBeutelMESchulzA, et al. Is assessment of depression equivalent for migrants of different cultural backgrounds? Results from the German population-based Gutenberg Health Study (GHS). Depress Anxiety2018; 35(12): 1178-1189.
36.
ReichHRiefWBrählerE, et al. Cross-cultural validation of the German and Turkish versions of the PHQ-9: an IRT approach. BMC Psychol2018; 6(1): 26.
37.
BreitbartWPessinHRosenfeldB, et al. Individual meaning-centered psychotherapy for the treatment of psychological and existential distress: a randomized controlled trial in patients with advanced cancer. Cancer2018; 24(15): 3231–3239.
38.
FitzgeraldPLoCLiM, et al. The relationship between depression and physical symptom burden in advanced cancer. BMJ Support Palliat Care2015; 5(4): 381–388.
39.
GrunkeBPhilippRVehlingS, et al. Measuring the psychosocial demensions of quality of life in patients with advanced cancer: psychometrics of the german quality of life at the end of life-cancer psychosocial questionnaire. J Pain Symptom Manage2018; 55(3): 985–991.e1.
40.
GrotmolKSLieHCLogeJH, et al. Patients with advanced cancer and depression report a significantly higher symptom burden than non-depressed patients. Palliat Support Care2019; 17(2): 143–149.
41.
KrauseSRydallAHalesS, et al. Initial validation of the Death and Dying Distress Scale for the assessment of death anxiety in patients with advanced cancer. J Pain Symptom Manage2015; 49: 126–134.
42.
ScheffoldKPhilippRVehlingS, et al. Spiritual well-being mediates the association between attachment. Support Care Cancer2019; 27(11): 4317–4325.
43.
LoCBurmanDSwamiN, et al. Validation of the QUAL-EC for assessing quality of life in patients with advanced cancer. Eur J Cancer2011; 47: 554–560.
44.
LoCWalshAMikulincerM, et al. Measuring attachment security in patients with advanced cancer: psychometric properties of a modified and brief Experiences in Close Relationships scale. Psycho-Oncology2009; 18: 490–499.
45.
KarnofskyDABurchenalJH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeodCM (ed.) Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949, pp. 191–205.
46.
PortenoyRKThalerHTKornblithAB, et al. The Memorial Symptom Assessment Scale: An instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer1994; 30A(9): 1326–1336.
47.
ChangVTHwangSSFeuermanM, et al. The memorial symptom assessment scale short form (MSAS-SF). Cancer2000; 89(5): 1162–1171.
48.
SpitzerRLKroenkeKWilliamsJB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med2006; 166: 1092–1097.
49.
SteinhauserKEBosworthHBClippEC, et al. Initial assessment of a new instrument to measure quality of life at the end of life. J Palliat Med2002; 5: 829–841.
50.
KissaneDWWeinSLoveA, et al. The Demoralization Scale: a report of its development and preliminary validation. J Palliat Care2004; 20(4): 269–276.
51.
PetermanAHFitchettGBradyMJ, et al. Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy – spiritual well-being scale (FACIT-Sp). Ann Behav Med2002; 24(1): 49–58.
52.
GreenSB.How many subjects deos it take to do a regression analysis?Multivar Behav Res1991; 26: 449–510.
53.
FieldA.Discovering Statistics Using SPSS. 3rd ed.London: SAGE Publications Ltd, 2009.
54.
PlumbMHollandJC.Comparative studies of psychological function in patients with advanced cancer: self-reported depressive symptoms. Psychosom Med1977; 39: 264–276.
55.
Kautzky-WillerA.Gender medicine: sex- and gender-specific aspects of clinical medicine. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz2014; 57: 1022–1030.
56.
KathleenEllSanchezKVourlekisB, et al. Depression, correlates of depression, and receipt of depression care among low-income females with breast or gynecological cancer. J Clin Oncol2005; 23(13): 3052–3060.
57.
FagundesCJonesDVichayaE, et al. Socioeconomic status is associated with depressive severity among patients with advanced non-small-cell lung cancer: treatment setting and minority status do not make a difference. J Thorac Oncol2014; 9(10): 1459–1463.
58.
GreenCRMontagueLHart-JohnsonTA.Consistent and breakthrough pain in diverse advanced cancer patients: a longitudinal examination. J Pain Symptom Manage2009; 37(5): 831–847.
59.
ReisnerSLBielloKRosenbergerJG, et al. Using a two-step method to measure transgender identity in Latin America/the Caribbean, Portugal, and Spain. Arch Sex Behav2014; 43(8): 1503–1514.
60.
PintoADAratangyTAbramovichA, et al. Routine collection of sexual orientation and gender identity data: a mixed-methods study. CMAJ2019; 191(3): E63–E68.
